European bat lyssavirus 1 is a species of lyssavirus that circulates in European bats and causes fatal rabies-like encephalitis in bats and occasionally in other mammals, including humans.
Explanation
European bat lyssavirus 1 (EBLV‑1) belongs to the genus Lyssavirus in the family Rhabdoviridae. Lyssaviruses are negative‑sense single‑stranded RNA viruses that cause rabies and rabies‑like diseases. EBLV‑1 was first isolated in 1954 from a Serotine bat (Eptesicus serotinus) in Germany and is now recognised as the most widespread lyssavirus among insectivorous bats in Europe. The genome is about 12 kilobases and encodes five proteins: nucleoprotein, phosphoprotein, matrix, glycoprotein and large polymerase. Phylogenetic analyses divide EBLV‑1 into two sublineages, EBLV‑1a and EBLV‑1b, with distinct geographical distributions across western and central Europe. The virus replicates in neural tissue and is shed in saliva, facilitating transmission by bites. Serotine bats and closely related species serve as primary reservoirs, but antibodies and viral RNA have been detected in other genera. Spillover infections to cats, sheep and humans have occurred, though they are rare. In infected mammals the disease resembles classical rabies, with behavioural changes, paralysis and fatal encephalitis. Human cases have been fatal, underscoring the importance of post‑exposure prophylaxis following bat bites. Laboratory studies show that current rabies vaccines and immunoglobulins confer cross‑protection against EBLV‑1 due to antigenic similarities among lyssaviruses.
Notable Cases and Public Health Measures
Only a few human infections with EBLV‑1 have been documented. A fatal case was reported in 2002 in a bat handler in Scotland, and earlier cases occurred in Ukraine and Russia. Domestic animals such as cats and sheep have also contracted the virus after interacting with infected bats. Surveillance of bat populations in Spain, France, Germany and other European countries has revealed seroprevalence rates ranging from 1 % to more than 20 %, indicating sustained circulation in certain colonies. Public health guidance emphasises avoiding direct contact with bats and seeking rabies vaccination for professional bat handlers. Post‑exposure prophylaxis with rabies vaccine and immunoglobulin is advised following any bat bite or scratch. Continued monitoring of bat populations and sequencing of viral isolates are important for understanding the distribution and evolution of EBLV‑1. EBLV‑1 is a distinct lyssavirus maintained in European bat populations. Although spillover to humans is rare, the disease is invariably fatal without prompt prophylaxis. Awareness and vaccination of high‑risk individuals remain the principal measures for prevention. Related Terms: Rabies virus, Lyssavirus, European Bat Lyssavirus 2, Australian Bat Lyssavirus, Duvenhage virus